Market-ready wearable myopia device anticipated for 2021
Click Here to Manage Email Alerts
A proof-of-concept clinical study showed changes in axial length resulting from the use of a wearable myopia control device that replicated changes previously achieved with a bench top device.
The device uses Kubota Glasses technology, which projects myopically defocused virtual images on the peripheral visual field to actively stimulate the retina, Kubota Vision Inc. said in a press release.
By actively stimulating the retina for shorter periods, Kubota Glasses’ goal is to reduce the progression of myopia while maintaining central vision and avoiding affecting the patient’s day-to-day life.
The study, which was conducted at the Manhattan Vision Associates’ Institute for Vision Research, monitored peripheral defocus on ocular biometrics. The 25 participants were between 18 and 35 years old.
“It is another great achievement that this [proof-of-concept] study using a wearable device demonstrated the same efficacy as a bench top device,” Kubota President and CEO Ryo Kubota, MD, PhD, said in the release. “We will continue our effort to produce more scientific evidence on Kubota Glasses technology through further clinical studies so that our wearable myopia device will soon become available to people in need.”
The clinical study that evaluated the efficacy of the bench top device found the test eye’s axial length decreases when the stimulus is applied, compared with the control eye.
Kubota Vision anticipates that a wearable prototype will be ready by the end of the year, with a product launch in 2021.
Read more about
Click Here to Manage Email Alerts